Journal
VIRUSES-BASEL
Volume 14, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/v14122778
Keywords
COVID-19 vaccines; mRNA vaccine; chronic liver disease; immunization; SARS-CoV-2
Categories
Ask authors/readers for more resources
Vaccination against SARS-CoV-2 is crucial for individuals with Chronic Liver Disease (CLD), as they have a decreased immune response and are vulnerable to severe COVID-19. However, the incidence of liver injury following vaccination is relatively rare. Timely vaccination and booster shots are necessary according to guidelines.
Vaccination against SARS-CoV-2 has become a central public health issue, primarily for vulnerable populations such as individuals with Chronic Liver Disease (CLD). Increased COVID-19-related mortality and disease severity has been noted in this subgroup of patients. Severe COVID-19 tends to further deregulate liver function in patients with chronic liver failure or cirrhosis and even reactivate hepatitis in people living with HBV or HCV. In addition, impaired hepatic function leads to several limitations in possible therapeutic interventions. Chronic hepatic dysregulation, along with the underlying cirrhosis-associated immune dysfunction (CAID), leads to a decreased immune response to vaccination that, in turn, may result in reduced efficacy rates and lowered lasting protection. According to current guidelines, timely vaccination and frequent booster shot administration are deemed necessary in this context. Vaccination-related adverse events are mostly mild in nature and similar to those reported in the general population, whereas the incidence of liver injury following vaccination is relatively rare. We aimed to review available evidence and recommendations associated with COVID-19 vaccination in patients with chronic liver disease, and provide insight to current issues and future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available